[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
MicroCap St0ck Alert
MicroCap St0ck Alert
Wed, 18 Aug 2004 10:48:52 +0000
The Growth St0ck Report
Genex Pharmaceuticals (OTCBB: GENX) Press Release
Genex Pharmaceutical Sees StrOng Earnings Gr0wth for 2004 and 2005
Tuesday August 17, 10:26 am ET
NEW YORK--(BUSINESS WIRE)--Aug. 17, 2004--Genex Pharmaceutical, Inc.
(stock symbol: GENX),a Delaware corporation, is a profitable biomedical
technology company with a unique product for treating various
bone-related injuries called Reconstituted Bone Xenograft (RBX).
Approved by the Chinese Food & Drug Administration, RBX is suitable for
compound or complex bone fractures, compression fractures and
intractable fractures, bone defects, vertebral column or joint
rehabilitation and for bone absence after tumor removal such as a bone
cyst. The company announced financial results for its second quarter
ending June 30, 2004. The following are some of the highlights in its
recent quarterly filing with the SEC:
432% in-crease in revenue for Q2 2004 compared to Q2 2003.
874% in-crease in revenue for 6 months ended June 30, 2004 compared to
same period last year.
Significant in-crease in net inc0me for Q2 2004 compared to Q2 2003 and
for the 6 month period ended June 30, 2004 as compared to same period
380% in-crease in Gr0ss Pr0fit for Q2 2004 compared to Q2 2003.
840% in-crease in Gr0ss Pr0fit for 6 months ended June 30, 2004 compared
to same period last year.
"We are seeing significant in-creases in revenues and pr0fitability as
we respond to growing customer demand for RBX. We see continued earnings
momentum for 2004 and 2005," said Chairman and Chief Executive Mr. Fuzhi
(Press Release Source: Genex Pharmaceutical, Inc.)
About Genex Pharmaceutical, Inc.
Genex Pharmaceutical, Inc. is a biomedical technology company with
distinctive proprietary technology for an orthopedic device that treats
bone-related injuries. Headquartered in Tianjin, China, the Company
manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400
hospitals in 22 provinces throughout mainland China. RBX offers a modern
alternative to traditional methods of treating orthopedic injuries.
Good Luck and Succesful Trading. Go GENEX!!
DISCL-AIMER: Information within this em-ail contains "F0RWARD looking
statements" within the meaning of Section 27A of the Securities Act of
1933 and Section 21B of the Securities Exchange Act of 1934. Any
statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not statements of
historical fact and may be "F0RWARD looking statements."F0RWARD looking
statements are based on expectations, estimates and projections at the
time the statements are made that involve a number of risks and
uncertainties which could cause actual results or events to differ
materially from those presently anticipated. F0RWARD looking statements
in this action may be identified through the use of words such as
"projects", "foresee", "expects", "will," "anticipates," "estimates,"
"believes," "understands" or that by statements indicating certain
actions "may," "could," or "might" occur. As with many micro-cap stocks,
today's company has additional risk factors worth noting. Those factors
include:a limited operating history, the company advancing cash to
related parties and a shareholder on an unsecured basis: one vendor, a
related party through a majority stockholder, supplies ninety-seven
percent of the company's raw materials: reliance on two customers for
over fifty percent of their business and numerous related party
transactions and the need to raise capital.These factors and others are
more fully spelled out in the company's SEC filings. We urge you to read
the those filings before you invest. The Growth ST0CK Report does not
represent that the information contained in this message states all
material facts or does not omit a material fact necessary to make the
statements therein not misleading. All information provided within this
em-ail pertaining to investing, ST0CKS, securities must be understood as
information provided and not investment advice. The Growth ST0CK Report
advises all readers and subscribers to seek advice from a registered
professional securities representative before deciding to trade in
ST0CKS featured within this ema-il. None of the material within this
report shall be construed as any kind of investment advice or
solicitation.Many of these companies are on the verge of bankruptcy. You
can lose all your M0NEY by investing in this ST0CK. The publisher of The
Growth ST0CK Report is not a registered investment ADVIS0R. Subscribers
should not view information herein as legal, tax, accounting or
investment advice. Any reference to past performance(s) of companies are
specially selected to be referenced based on the favorable performance
of these companies. You would need perfect timing to acheive the results
in the examples given. There can be no assurance of that happening.
Remember, as always, past performance is never indicative of future
results and a thorough due diligence effort, including a review of a
company's filings, should be completed prior to investing. In compliance
with the Securities Act of 1933, Section 17(b),The Growth ST0CK Report
discloses the receipt of twelve thousand D0LLARS from a third party
(DMI,Inc.), not an officer, director or affiliate shareholder for the
circulation of this report. DMI, Inc. has a position in the ST0CK they
will sell at any time without notice. Be aware of an inherent conflict
of interest resulting from such compensation due to the fact that this
is a paid adver-tisement and we are conflicted. All factual information
in this report was gathered from public sources, including but not
limited to Company Websites, SEC Filings and Company Press Releases. The
Growth ST0CK Report believes this information to be reliable but can
make no guarantee as to its accuracy or completeness. Use of the
material within this em-ail constitutes your acceptance of these terms.
|[Prev in Thread]
||[Next in Thread]|
- MicroCap St0ck Alert,
Florine Kay <=